Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

NCRI 2019 | CAR T-cell therapy toxicities in B-cell lymphomas

Jakub Svoboda • 8 Nov 2019
NCRI 2019
B-Cell Lymphoma Lymphoma

Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, talks about CAR T-cell therapy toxicities in B-cell lymphomas. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Jakub Svoboda

Combined chemotherapy and consolidative radiation versus chemotherapy alone in early-stage cHL 3:21
Combined chemotherapy and consolidative radiation versus chemotherapy alone in early-stage cHL
Jakub Svoboda • 7 Dec 2025
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure 3:36
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda • 7 Dec 2025
BrECADD versus BEACOPP in advanced HL: a German Hodgkin Study Group investigation 1:37
BrECADD versus BEACOPP in advanced HL: a German Hodgkin Study Group investigation
Jakub Svoboda • 2 Jun 2024
Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment 2:13
Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment
Jakub Svoboda • 2 Jun 2024

Related Videos

A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL 1:58
A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur • 8 Dec 2025
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO 2:24
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq • 8 Dec 2025
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7 2:53
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
Lori Leslie • 7 Dec 2025
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL 1:35
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals